In order to better understand neurodegeneration in SMA, some efforts to characterize the disease at baseline in clinical and biochemical aspects have been made: Kolb et al. found altered electrophysiological and plasma protein parameters and lower SMN mRNA levels in SMA patients than in the control group. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.